Isotopia Molecular Imaging of Israel has signed a production agreement for no-carrier-added lutetium-177 (n.c.a. Lu-177) with radiopharmaceutical manufacturer Centre for Probe Development and Commercialization (CPDC) of Canada.
CPDC will produce n.c.a. Lu-177, which is used in targeted radionuclide therapy, in collaboration with Isotopia for distribution in North America, according to the companies.
